Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HTIG/TAT/F(ab')₂

PreclinicalSmall molecule

ZZhuhai Trinomab Pharmaceutical Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2029

Tetanus

NCT07347938

Clinical

Trials by Indication[1]

Tetanus1 trial

A Multicenter, Prospective, Non-Randomized, Open-Label, Active-Controlled Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Recruiting·ZZhuhai Trinomab Pharmaceutical Co., Ltd.··NCT07347938·6,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HTIG/TAT/F(ab')₂. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HTIG/TAT/F(ab')₂ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HTIG/TAT/F(ab')₂. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhuhai Trinomab Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhuhai Trinomab Pharmaceutical Co., Ltd.

Related News